BAJAJ BROKING
Caplin Point Laboratories’ Gummidipoondi unit passed the US FDA inspection with zero 483 observations. The inspection focused on Good Manufacturing Practices, enhancing Caplin Point Laboratories Ltd share price prospects.
Caplin Point Laboratories Ltd has announced a significant regulatory milestone. Its Gummidipoondi-based sterile injectable and ophthalmic manufacturing facility received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA). The unannounced inspection, conducted from 5 to 9 August 2024, concluded with zero 483 observations. This outcome demonstrates Caplin Point’s robust adherence to Good Manufacturing Practices (GMP) and other regulatory standards, further strengthening its reputation in the pharmaceutical industry.
Also read: Reliance Consumer Products launches RasKik Gluco Energy at ₹10
Inspection Dates: 5–9 August 2024
Facility Location: Gummidipoondi, Tamil Nadu
Inspection Outcome: Zero 483 observations
Report Status: Establishment Inspection Report (EIR) issued
Regulatory Focus: Good Manufacturing Practices compliance
Also read: Bharti Airtel to sell 50% stake in Firefly Networks for ₹45 million
The inspection was a routine regulatory check to assess the facility’s compliance with FDA regulations, including GMP. The zero 483 observations highlight the company’s dedication to maintaining high manufacturing standards. Caplin Steriles, a subsidiary of Caplin Point Laboratories Ltd, oversees the production of injectable and ophthalmic products at this unit, ensuring quality consistency for global markets.
Following the announcement, Caplin Point Laboratories Ltd share price closed at ₹2,521.05, marking a decline of ₹15.45 or 0.61% on the Bombay Stock Exchange (BSE). Despite this minor dip, the successful FDA inspection positions the company well for sustained growth in international markets.
Details | Data |
Inspection Dates | 5–9 August 2024 |
Facility Location | Gummidipoondi, Tamil Nadu |
FDA Report Received | 6 January 2025 |
Observations | Zero 483 observations |
Caplin Point Laboratories Ltd Share Price | ₹2,521.05 |
Caplin Point’s successful FDA inspection underscores its commitment to regulatory excellence and high-quality manufacturing. This development strengthens its market presence and potential to capture international opportunities.
Also read: Ashoka Buildcon secures ₹1,391-crore NHAI project in West Bengal
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading